Articles

Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ

Accumulation of amyloid β (Aβ) in the brain is proposed as a cause of Alzheimer’s disease (AD), with Aβ oligomers hypothesized to be the primary mediators of neurotoxicity. Crenezumab is a humanized immunoglob...

Authors: William J. Meilandt, Janice A. Maloney, Jose Imperio, Guita Lalehzadeh, Tim Earr, Susan Crowell, Travis W. Bainbridge, Yanmei Lu, James A. Ernst, Reina N. Fuji and Jasvinder K. Atwal

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association...

Authors: Virginia Pérez-Grijalba, Javier Arbizu, Judith Romero, Elena Prieto, Pedro Pesini, Leticia Sarasa, Fernando Guillen, Inmaculada Monleón, Itziar San-José, Pablo Martínez-Lage, Josep Munuera, Isabel Hernández, Mar Buendía, Oscar Sotolongo-Grau, Montserrat Alegret, Agustín Ruiz…

Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on diagnostic confidence and diagnostic accuracy

The development of diagnostic tools capable of accurately identifying the pathophysiology of mild cognitive impairment (MCI) has become a crucial target considering the claim that disease-modifying treatments ...

Authors: Alessandro Padovani, Alberto Benussi, Maria Sofia Cotelli, Clarissa Ferrari, Valentina Cantoni, Valentina Dell’Era, Rosanna Turrone, Barbara Paghera and Barbara Borroni

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers

Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ₄₂ and Aβ₄₀) and ne...

Authors: Nicholas J. Ashton, Marc Suárez-Calvet, Amanda Heslegrave, Abdul Hye, Cristina Razquin, Pau Pastor, Raquel Sanchez-Valle, José L. Molinuevo, Pieter Jelle Visser, Kaj Blennow, Angela K. Hodges and Henrik Zetterberg

Systemic and central nervous system metabolic alterations in Alzheimer’s disease

Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer’s disease (AD) on both the systemic and c...

Authors: Vera van der Velpen, Tony Teav, Héctor Gallart-Ayala, Florence Mehl, Ioana Konz, Christopher Clark, Aikaterini Oikonomidi, Gwendoline Peyratout, Hugues Henry, Mauro Delorenzi, Julijana Ivanisevic and Julius Popp

Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials

Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early...

Authors: Michelle M. Nuño, Daniel L. Gillen and Joshua D. Grill

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

Ongoing efforts within the Alzheimer’s disease (AD) field have focused on improving the intra- and inter-laboratory variability for cerebrospinal fluid (CSF) biomarkers. Fully automated assays offer the possib...

Authors: Maria João Leitão, Anuschka Silva-Spínola, Isabel Santana, Veronica Olmedo, Alicia Nadal, Nathalie Le Bastard and Inês Baldeiras

Retinal thinning of inner sub-layers is associated with cortical atrophy in a mouse model of Alzheimer’s disease: a longitudinal multimodal in vivo study

It has been claimed that the retina can be used as a window to study brain disorders. However, concerning Alzheimer’s disease (AD), it still remains controversial whether changes occurring in the brain and ret...

Authors: Samuel Chiquita, Elisa J. Campos, João Castelhano, Mário Ribeiro, José Sereno, Paula I. Moreira, Miguel Castelo-Branco and António Francisco Ambrósio

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease

The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ) were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) bet...

Authors: Xue Meng, Tao Li, Xiao Wang, Xiaozhen Lv, Zhiyu Sun, Jichun Zhang, Feng Su, Sungmin Kang, SangYun Kim, Seong Soo A. An, Xin Yu, Chen Zhang and Huali Wang

Age-dependent emergence of neurophysiological and behavioral abnormalities in progranulin-deficient mice

Loss-of-function mutations in the progranulin gene cause frontotemporal dementia, a genetic, heterogeneous neurodegenerative disorder. Progranulin deficiency leads to extensive neuronal loss in the frontal and...

Authors: Dávid Nagy, Lauren Herl Martens, Liza Leventhal, Angela Chen, Craig Kelley, Milan Stoiljkovic and Mihály Hajós

Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer’s disease

Physical activity might reduce the risk of developing dementia. However, it is still unclear whether the protective effect differs depending on the subtype of dementia. We aimed to investigate if midlife physi...

Authors: Oskar Hansson, Martina Svensson, Anna-Märta Gustavsson, Emelie Andersson, Yiyi Yang, Katarina Nägga, Ulf Hållmarker, Stefan James and Tomas Deierborg

Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation

Repeated failure of drug candidates targeting Alzheimer’s disease (AD) in clinical trials likely stems from a lack of understanding of the molecular mechanisms underlying AD pathogenesis. Recent research has h...

Authors: Woo Shik Shin, Jing Di, Qin Cao, Binsen Li, Paul M. Seidler, Kevin A. Murray, Gal Bitan and Lin Jiang

Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy

Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study...

Authors: Mary M. Ryan, Joshua D. Grill and Daniel L. Gillen

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes

According to the 2018 NIA-AA research framework, Alzheimer’s disease (AD) is not defined by the clinical consequences of the disease, but by its underlying pathology, measured by biomarkers. Evidence of both a...

Authors: Tiziana Carandini, Andrea Arighi, Luca Sacchi, Giorgio G. Fumagalli, Anna M. Pietroboni, Laura Ghezzi, Annalisa Colombi, Marta Scarioni, Chiara Fenoglio, Milena A. De Riz, Giorgio Marotta, Elio Scarpini and Daniela Galimberti

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies

One of the major challenges in diagnosing dementia with Lewy bodies (DLB) is the common co-morbid presence of amyloid pathology. To understand the putative role of altered amyloid-β (Aβ) metabolism in dementia...

Authors: Inger van Steenoven, Wiesje M. van der Flier, Philip Scheltens, Charlotte E. Teunissen and Afina W. Lemstra

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer’s disea...

Authors: Simon Sjödin, Gunnar Brinkmalm, Annika Öhrfelt, Lucilla Parnetti, Silvia Paciotti, Oskar Hansson, John Hardy, Kaj Blennow, Henrik Zetterberg and Ann Brinkmalm

CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology

We aimed to assess the relationship between levels of a cerebrospinal fluid (CSF) marker of pericyte damage, soluble platelet-derived growth factor receptor β (sPDGFRβ) and CSF markers of blood-brain barrier (...

Authors: J. S. Miners, P. G. Kehoe, S. Love, H. Zetterberg and K. Blennow

Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas

Up to 20% of patients with AD experience hallucinations. The pathological substrate is not known. Visual hallucinations (VH) are more common in dementia with Lewy bodies (DLB). In autopsy studies, up to 60% of...

Authors: Lindsey Isla Sinclair, Amit Kumar, Taher Darreh-Shori and Seth Love

Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies

Very little is known for the direction or causality of the relationship between lifetime sleep experiences and in vivo Alzheimer’s disease (AD) pathologies. This study aimed to examine the relationship between...

Authors: Young Min Choe, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Bo Kyung Sohn, Yu Kyeong Kim, Seong A Shin, Chul-Ho Sohn, Yu Jin Lee and Dong Young Lee

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

In vivo, high cerebral amyloid-β load has been associated with (i) reduced concentrations of Aβ₄₂ in cerebrospinal fluid and (ii) increased retention using amyloid-β positron emission tomography. Although these t...

Authors: Arno de Wilde, Juhan Reimand, Charlotte E. Teunissen, Marissa Zwan, Albert D. Windhorst, Ronald Boellaard, Wiesje M. van der Flier, Philip Scheltens, Bart N. M. van Berckel, Femke Bouwman and Rik Ossenkoppele

ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics

Information given to patients and caregivers during the clinician-patient encounter varies considerably between memory clinic professionals. Patients and caregivers express a clear desire for more information....

Authors: Agnetha D. Fruijtier, Leonie N. C. Visser, Ingrid S. van Maurik, Marissa D. Zwan, Femke H. Bouwman, Wiesje M. van der Flier and Ellen M. A. Smets

The “rights” of precision drug development for Alzheimer’s disease

There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages i...

Authors: Jeffrey Cummings, Howard H. Feldman and Philip Scheltens

Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer’s disease: a preclinical study in rTg4510 mice

The lack of effective treatment options for Alzheimer’s disease (AD) is of momentous societal concern. Synaptic loss is the hallmark of AD that correlates best with impaired memory and occurs early in the dise...

Authors: Joshua B. Foster, Rashelle Lashley, Fangli Zhao, Xueqin Wang, Nydia Kung, Candice C. Askwith, Lin Lin, Michael W. Shultis, Kevin J. Hodgetts and Chien-Liang Glenn Lin

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey

The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was consider...

Authors: Daniela Bertens, Stephanie Vos, Patrick Kehoe, Henrike Wolf, Flavio Nobili, Alexandre Mendonça, Ineke van Rossum, Jacub Hort, Jose Luis Molinuevo, Michael Heneka, Ron Petersen, Philip Scheltens and Pieter Jelle Visser

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis ...

Authors: Jeffrey Cummings, Peter Passmore, Bernadette McGuinness, Vincent Mok, Christopher Chen, Sebastiaan Engelborghs, Michael Woodward, Sagrario Manzano, Guillermo Garcia-Ribas, Stefano Cappa, Paulo Bertolucci and Leung-Wing Chu

Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI

Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of Alzheimer’s disease (AD) pathophysiologic continuum constituting what has been established as “AD signature”. To what e...

Authors: Paula M. Petrone, Adrià Casamitjana, Carles Falcon, Miquel Artigues, Grégory Operto, Raffaele Cacciaglia, José Luis Molinuevo, Verónica Vilaplana and Juan Domingo Gispert

A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain

Alzheimer’s disease (AD) is the most common form of dementia. This neurodegenerative disorder is associated with neuronal death and gliosis heavily impacting the cerebral cortex. AD has a substantial but heter...

Authors: Jorge L. Del-Aguila, Zeran Li, Umber Dube, Kathie A. Mihindukulasuriya, John P. Budde, Maria Victoria Fernandez, Laura Ibanez, Joseph Bradley, Fengxian Wang, Kristy Bergmann, Richard Davenport, John C. Morris, David M. Holtzman, Richard J. Perrin, Bruno A. Benitez, Joseph Dougherty…

Depression, subjective cognitive decline, and the risk of neurocognitive disorders

Depression and subjective cognitive decline (SCD) both predict neurocognitive disorders (NCD). However, the two correlate strongly with each other. It remains uncertain whether they reflect independent neurobi...

Authors: Tau Ming Liew

Music and emotion in Alzheimer’s disease

Alzheimer’s disease may compromise several musical competences, though no clear data is available in the scientific literature. Furthermore, music is capable of communicating basic emotions, but little is know...

Authors: Eva M. Arroyo-Anlló, Stéphanie Dauphin, M. Noelle Fargeau, Pierre Ingrand and Roger Gil

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assis...

Authors: Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines and David Michelson

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal mo...

Authors: Matthias Brendel, Maximilian Deussing, Tanja Blume, Lena Kaiser, Federico Probst, Felix Overhoff, Finn Peters, Barbara von Ungern-Sternberg, Sergey Ryazanov, Andrei Leonov, Christian Griesinger, Andreas Zwergal, Johannes Levin, Peter Bartenstein, Igor Yakushev, Paul Cumming…

Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study

Subjective cognitive decline (SCD) has been proposed as a pre-MCI at-risk condition of Alzheimer’s disease (AD). Current research is focusing on a refined assessment of specific SCD features associated with in...

Authors: Lisa Miebach, Steffen Wolfsgruber, Alexandra Polcher, Oliver Peters, Felix Menne, Katja Luther, Enise Incesoy, Josef Priller, Eike Spruth, Slawek Altenstein, Katharina Buerger, Cihan Catak, Daniel Janowitz, Robert Perneczky, Julia Utecht, Christoph Laske…

Tau and atrophy: domain-specific relationships with cognition

Late-onset Alzheimer’s disease (AD) is characterized by primary memory impairment, which then progresses towards severe deficits across cognitive domains. Here, we report how performance in cognitive domains r...

Authors: Leonardino A. Digma, John R. Madsen, Emilie T. Reas, Anders M. Dale, James B. Brewer and Sarah J. Banks

Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set

Longitudinal investigations are needed to improve understanding of the contributions of cerebral small vessel disease to the clinical manifestation of Alzheimer’s disease, particularly in the early disease sta...

Authors: Christian Puzo, Caroline Labriola, Michael A. Sugarman, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Thor D. Stein, Neil W. Kowall, Ann C. McKee, Jesse Mez, Ronald J. Killiany, Robert A. Stern and Michael L. Alosco

Towards a unified protocol for handling of CSF before β-amyloid measurements

Widespread implementation of Alzheimer’s disease biomarkers in routine clinical practice requires the establishment of standard operating procedures for pre-analytical handling of cerebrospinal fluid (CSF).

Authors: Shorena Janelidze, Erik Stomrud, Britta Brix and Oskar Hansson

Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease

Retinal thickness can be measured non-invasively with optical coherence tomography (OCT) and may offer compelling potential as a biomarker for Alzheimer’s disease (AD). Retinal thinning is hypothesized to be a...

Authors: Jurre den Haan, Lajos Csinscik, Tom Parker, Ross W. Paterson, Catherine F. Slattery, Alexander Foulkes, Femke H. Bouwman, Frank D. Verbraak, Philip Scheltens, Tunde Peto, Imre Lengyel, Jonathan M. Schott, Sebastian J. Crutch, Timothy J. Shakespeare and Keir X. X. Yong

Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time

Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer’s disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a m...

Authors: Elizabeth Kuhn, Inès Moulinet, Audrey Perrotin, Renaud La Joie, Brigitte Landeau, Clémence Tomadesso, Alexandre Bejanin, Siya Sherif, Vincent De La Sayette, Béatrice Desgranges, Denis Vivien, Géraldine Poisnel and Gaëlle Chételat

Associations between quantitative [¹⁸F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum

Neuropathological studies have linked tau aggregates to neuronal loss. To describe the spatial distribution of neurofibrillary tangle pathology in post-mortem tissue, Braak staging has been used. The aim of th...

Authors: Tessa Timmers, Rik Ossenkoppele, Emma E. Wolters, Sander C. J. Verfaillie, Denise Visser, Sandeep S. V. Golla, Frederik Barkhof, Philip Scheltens, Ronald Boellaard, Wiesje M. van der Flier and Bart N. M. van Berckel

An experimental model of Braak’s pretangle proposal for the origin of Alzheimer’s disease: the role of locus coeruleus in early symptom development

The earliest brain pathology related to Alzheimer’s disease (AD) is hyperphosphorylated soluble tau in the noradrenergic locus coeruleus (LC) neurons. Braak characterizes five pretangle tau stages preceding AD...

Authors: Abhinaba Ghosh, Sarah E. Torraville, Bandhan Mukherjee, Susan G. Walling, Gerard M. Martin, Carolyn W. Harley and Qi Yuan

Spermidine/spermine-N¹-acetyltransferase ablation impacts tauopathy-induced polyamine stress response

Tau stabilizes microtubules; however, in Alzheimer’s disease (AD) and tauopathies, tau becomes hyperphosphorylated, aggregates, and results in neuronal death. Our group recently uncovered a unique interaction ...

Authors: Leslie A. Sandusky-Beltran, Andrii Kovalenko, Chao Ma, John Ivan T. Calahatian, Devon S. Placides, Mallory D. Watler, Jerry B. Hunt, April L. Darling, Jeremy D. Baker, Laura J. Blair, Mackenzie D. Martin, Sarah N. Fontaine, Chad A. Dickey, April L. Lussier, Edwin J. Weeber, Maj-Linda B. Selenica…

FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: a longitudinal study

Reduced ¹⁸F-fluorodeoxyglucose-positron emission tomography (FDG-PET) brain metabolism was recognized as a biomarker of neurodegeneration in the recently proposed ATN framework for Alzheimer’s disease (AD) biolog...

Authors: Ya-Nan Ou, Wei Xu, Jie-Qiong Li, Yu Guo, Mei Cui, Ke-Liang Chen, Yu-Yuan Huang, Qiang Dong, Lan Tan and Jin-Tai Yu

Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization

Intracerebral inoculation of extracts from post-mortem human Alzheimer’s disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the sy...

Authors: Cristina M. Pedrero-Prieto, Alicia Flores-Cuadrado, Daniel Saiz-Sánchez, Isabel Úbeda-Bañón, Javier Frontiñán-Rubio, Francisco J. Alcaín, Lourdes Mateos-Hernández, José de la Fuente, Mario Durán-Prado, Margarita Villar, Alino Martínez-Marcos and Juan R. Peinado

Frailty effects on non-demented cognitive trajectories are moderated by sex and Alzheimer’s genetic risk

Age-related frailty reflects cumulative multisystem physiological and health decline. Frailty increases the risk of adverse brain and cognitive outcomes, including differential decline and dementia. In a longi...

Authors: Sherilyn Thibeau, Kirstie McDermott, G. Peggy McFall, Kenneth Rockwood and Roger A. Dixon

Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer’s disease

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine. Chronic inflammation induced by amyloid β proteins (Aβ) is one prominent neuropathological feature in Alzheimer’s disease (AD) brain.

Authors: Si Zhang, Jiehao Zhao, Yuhu Zhang, Yun Zhang, Fang Cai, Lijuan Wang and Weihong Song

Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimo...

Authors: Ruth Stephen, Yawu Liu, Tiia Ngandu, Riitta Antikainen, Juha Hulkkonen, Juha Koikkalainen, Nina Kemppainen, Jyrki Lötjönen, Esko Levälahti, Riitta Parkkola, Pauliina Pippola, Juha Rinne, Timo Strandberg, Jaakko Tuomilehto, Ritva Vanninen, Miia Kivipelto…

Avoiding methodological bias in studies of amyloid imaging results disclosure

Authors: Carl Taswell, Cheryl Donohue, Maree T. Mastwyk, Andrea G. Louey, Jacqueline Giummarra, Joanne Robertson, David G. Darby, Colin L. Masters and Christopher C. Rowe

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”

Authors: Joshua D. Grill, Chelsea G. Cox, Kristin Harkins and Jason Karlawish

Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers

Subjective cognitive decline (SCD) is characterized by self-reported cognitive deficits without measurable cognitive impairment. It has been suggested that individuals with SCD exhibited brain structural alter...

Authors: Yu Sun, Xiaoni Wang, Yinshan Wang, Haoming Dong, Jie Lu, Tohar Scheininger, Michael Ewers, Frank Jessen, Xi-Nian Zuo and Ying Han

Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia

Alzheimer’s disease (AD) prevalence is rapidly growing as worldwide populations grow older. Available treatments have failed to slow down disease progression, thus increasing research focus towards early or pr...

Authors: David López-Sanz, Ricardo Bruña, María Luisa Delgado-Losada, Ramón López-Higes, Alberto Marcos-Dolado, Fernando Maestú and Stefan Walter

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study

Neuropsychiatric symptoms (NPS) are very common in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia and are associated with various disadvantageous clinical outcomes includin...

Authors: Willem S. Eikelboom, Ellen Singleton, Esther van den Berg, Michiel Coesmans, Francesco Mattace Raso, Rozemarijn L. van Bruchem, Jeannette A. Goudzwaard, Frank Jan de Jong, Marc Koopmanschap, Tom den Heijer, Jan J. M. Driesen, Lilian J. H. M. Vroegindeweij, Elsbeth C. Thomeer, Susanne E. Hoogers, Anke A. Dijkstra, Sytse U. Zuidema…